GenMont Biotech Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, sales was TWD 186.45 million compared to TWD 203.24 million a year ago. Net income was TWD 35.02 million compared to TWD 45.36 million a year ago. Basic earnings per share from continuing operations was TWD 0.41 compared to TWD 0.53 a year ago. Diluted earnings per share from continuing operations was TWD 0.4 compared to TWD 0.52 a year ago.